An Open-label Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Intramuscular Injection of TAK-850 in Healthy Adult Subjects
Latest Information Update: 07 Jan 2022
At a glance
- Drugs TAK 850 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Takeda
Most Recent Events
- 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
- 18 Apr 2014 New trial record